此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

灵芝提取物治疗使用芳香酶抑制剂的乳腺癌患者的疲劳和/或关节痛/肌痛

2026年11月2日 更新者:Mayo Clinic

灵芝提取物治疗使用芳香酶抑制剂的乳腺癌患者的疲劳和/或关节痛:一项随机 II 期 MNCCTN 试验

This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of 1,000 mg three times daily (TID) of Reishi mushroom extracts as therapy for cancer-related fatigue measured by uniscale measurement at the end of four weeks.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of Reishi mushroom extracts as therapy for cancer-related arthralgias at the end of four weeks and four weeks after cross-over as measured by the Brief Pain index (BPI)-adapted for AI associated arthralgias.

II. To evaluate the effect of Reishi mushroom extracts on cancer-related quality of life (QOL), as measured by uniscale, at the end of four weeks and four weeks after cross-over.

III. To evaluate the efficacy of Reishi mushroom extracts on mood, as assessed by the World Health Organization Five Well-Being Index (WHO-5) item well-being scale, at the end of four weeks and four weeks after cross-over.

IV. To evaluate treatment toxicity between the two treatment arms, as measured by a patient symptom experience diary and weekly calls from the study team.

V. To evaluate the interest, knowledge, and acceptance of integrative treatments for cancer-related symptoms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive Reishi mushroom extract orally (PO) TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

研究类型

介入性

注册 (估计的)

80

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Minnesota
      • Albert Lea、Minnesota、美国、56007
        • 主动,不招人
        • Mayo Clinic Health System in Albert Lea
      • Baxter、Minnesota、美国、56425
        • 主动,不招人
        • Essentia Health Baxter Clinic
      • Bemidji、Minnesota、美国、56601
        • 主动,不招人
        • Sanford Joe Lueken Cancer Center
      • Brainerd、Minnesota、美国、56401
        • 主动,不招人
        • Essentia Health Saint Joseph's Medical Center
      • Deer River、Minnesota、美国、56636
        • 主动,不招人
        • Essentia Health Deer River Clinic
      • Detroit Lakes、Minnesota、美国、56501
        • 主动,不招人
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth、Minnesota、美国、55805
        • 主动,不招人
        • Essentia Health Cancer Center
      • Ely、Minnesota、美国、55731
        • 主动,不招人
        • Essentia Health Ely Clinic
      • Fosston、Minnesota、美国、56542
        • 主动,不招人
        • Essentia Health Fosston
      • Grand Rapids、Minnesota、美国、55744
        • 主动,不招人
        • Fairview Grand Itasca Clinic & Hospital
      • Hibbing、Minnesota、美国、55746
        • 主动,不招人
        • Essentia Health Hibbing Clinic
      • Hibbing、Minnesota、美国、55746
        • 主动,不招人
        • Fairview Range Medical Center
      • International Falls、Minnesota、美国、56649
        • 主动,不招人
        • Essentia Health International Falls Clinic
      • Mankato、Minnesota、美国、56001
        • 主动,不招人
        • Mayo Clinic Health Systems-Mankato
      • Monticello、Minnesota、美国、55362
        • 撤销
        • MMCORC CentraCare Monticello Cancer Center
      • Moose Lake、Minnesota、美国、55767
        • 主动,不招人
        • Essentia Health Moose Lake
      • Park Rapids、Minnesota、美国、56470
        • 主动,不招人
        • Essentia Health Park Rapids
      • Princeton、Minnesota、美国、55731
        • 主动,不招人
        • Fairview Northland Medical Center
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic in Rochester
        • 首席研究员:
          • Stacy D. D'Andre, M.D.
        • 接触:
      • Sandstone、Minnesota、美国、55072
        • 主动,不招人
        • Essentia Health Sandstone
      • Thief River Falls、Minnesota、美国、56701
        • 主动,不招人
        • Sanford Thief River Falls Medical Center
      • Virginia、Minnesota、美国、55792
        • 主动,不招人
        • Essentia Health Virginia Clinic
      • Worthington、Minnesota、美国、56187
        • 主动,不招人
        • Sanford Worthington Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Age ≥ 18 years
  • History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
  • Fatigue ≥ 4/10
  • Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
  • Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
  • On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
  • If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
  • White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior to randomization)
  • Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
  • Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
  • Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
  • Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
  • Provide informed consent
  • Ability to complete questionnaires
  • Willing to return to enrolling institution during the active monitoring phase of the study
  • Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration

Exclusion Criteria:

  • Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis

  • Allergy to mushrooms

  • On anticoagulation medication or aspirin or having a known bleeding disorder

  • On any specific medication for fatigue (e.g., methylphenidate)

  • Metastatic cancer diagnosis (history of nodal metastases is allowed)

  • Chronic steroid use, unless on physiologic replacement doses

  • Current use of any medical mushrooms

  • On medications for diabetes

  • History of symptomatic hypotension

  • Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems

  • Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline

  • Taking olaparib

  • Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:

    • Pregnant persons
    • Nursing persons
    • Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
  • Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm I (Reishi mushroom extract, placebo)

Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

Ancillary studies

其他名称:
  • 生活质量评估

Ancillary studies

Given PO

Given Reishi mushroom extract PO

其他名称:
  • 双孢蘑菇提取物
  • 栽培蘑菇
实验性的:Arm II (placebo, Reishi mushroom extract)

Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

Ancillary studies

其他名称:
  • 生活质量评估

Ancillary studies

Given PO

Given Reishi mushroom extract PO

其他名称:
  • 双孢蘑菇提取物
  • 栽培蘑菇

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in fatigue scores
大体时间:Baseline to end of four weeks

Based on a single item fatigue uniscale question. Will be compared between arms using a two-sided two-sample t-test assuming equal variances in each group.

Baseline to end of four weeks

次要结果测量

结果测量
措施说明
大体时间
Change in quality of life
大体时间:Baseline to the end of four weeks and four weeks after cross-over

Measured by the World Health Organization-Five Well-Being Index. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Baseline to the end of four weeks and four weeks after cross-over
Change in arthralgias
大体时间:Baseline to the end of four weeks and four weeks after cross-over

Measured by the Brief Pain Inventory for Aromatase Inhibitor Induced Arthralgia. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Baseline to the end of four weeks and four weeks after cross-over
Incidence of adverse events
大体时间:Up to 30 days follow-up

Measured by the symptom experience diary. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Up to 30 days follow-up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Stacy D. D'Andre, MD、Mayo Clinic in Rochester

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年10月18日

初级完成 (估计的)

2029年5月15日

研究完成 (估计的)

2029年6月15日

研究注册日期

首次提交

2023年8月31日

首先提交符合 QC 标准的

2023年8月31日

首次发布 (实际的)

2023年9月7日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • MC221002
  • MC221002 (其他标识符:Mayo Clinic in Rochester)
  • NCI-2023-06578 (注册表标识符:CTRP (Clinical Trials Reporting Program))
  • 23-005266 (其他标识符:Mayo Clinic Institutional Review Board)
  • MNCCTN032 (其他标识符:Minnesota Cancer Clinical Trials Network)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅